Kim Jeong Eun, Lee Chul, Park Kook In, Park Min Soo, Namgung Ran, Park In Kyu
Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea.
Korean J Pediatr. 2012 May;55(5):177-80. doi: 10.3345/kjp.2012.55.5.177. Epub 2012 May 21.
OK-432 (picibanil) is an inactivated preparation of Streptococcus pyogenes that causes pleurodesis by inducing a strong inflammatory response. Intrapleural instillation of OK-432 has recently been used to successfully treat neonatal and fetal chylothorax. Here we report a trial of intrapleural instillation of OK-432 in two preterm infants who were born with hydrops fetalis and massive bilateral pleural effusion. Both cases showed persistent pleural effusion, refractory to conservative treatment, up to postnatal days 26 and 46, respectively. An average of 80 to 140 mL of pleural fluid was drained daily. In case 1, the infant was treated with OK-432 during the fetal period at gestation 28 weeks and 4 days of gestation, but showed recurrence of pleural effusion and progressed into hydrops. Within two to three days after OK-432 injection, the amount of pleural fluid drainage was dramatically decreased and there was no reaccumulation. We did not observe any side effects related to OK-432 injection. We suggest that OK-432 should be considered as a therapeutic option in infants who have persistent pleural effusion for more than four weeks, with the expectation of the early removal of the chest tube and a good outcome.
OK-432(沙培林)是一种化脓性链球菌的灭活制剂,可通过引发强烈的炎症反应导致胸膜固定术。近期,胸腔内注入OK-432已被用于成功治疗新生儿和胎儿乳糜胸。在此,我们报告了对两名患有胎儿水肿和大量双侧胸腔积液的早产儿进行胸腔内注入OK-432的试验。两例均表现为持续性胸腔积液,分别在出生后第26天和第46天对保守治疗无效。每日平均引流出80至140毫升胸腔积液。病例1中,该婴儿在孕28周零4天时于胎儿期接受了OK-432治疗,但胸腔积液复发并进展为水肿。在注入OK-432后的两至三天内,胸腔引流量显著减少且未再积聚。我们未观察到与注入OK-432相关的任何副作用。我们建议,对于持续性胸腔积液超过四周的婴儿,应考虑将OK-432作为一种治疗选择,以期早期拔除胸管并获得良好预后。